US Archives - Page 94 of 131 - European Medical Journal

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.

Treg Cells: Helpers or Harmers in Arthritis?

Regulatory T (Treg) cells are vital for immune system balance, preventing autoimmune diseases by suppressing inflammation.

Epilepsy Prevention Using ARBs After Stroke: AES 2024

Stroke survivors with hypertension may have a new ally in reducing their risk of post-stroke epilepsy (PSE): angiotensin receptor blockers (ARBs).

Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

How Circadian Rhythms Impact Glioblastoma Growth

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Interview: Daniel Wallace

In the late 1980s and early 1990s, we were among the first to suggest that interleukin-6 played a role in lupus. It’s not specific just…

COPD Inhaler Safety: New Data Emerges

A recent study examining real-world COPD treatment outcomes has highlighted safety concerns regarding single-inhaler triple therapy compared to the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination, particularly in terms of cardiovascular risks.

Medical Histories That Defy Alzheimer’s

New research offers insights into medical factors linked to the absence of Alzheimer’s disease neuropathologic changes (ADNC) in individuals aged 90 and older.

PARP Inhibitor Shows Sustained Cancer Benefits: SABCS 2024

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.